Vyome Holdings Inc Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Vyome Holdings reported a net loss of $10.45 million in 2025 due to one-time merger and financing expenses. The company has $5 million in cash and no debt, and is advancing VT-1953, a treatment for malignant fungating wounds, which has shown positive Phase 2 results and has the potential to address a $2.2 billion market. However, the company's financial strategy relies heavily on cost management and capital allocation, and its future growth is uncertain without FDA approval for VT-1953.